Drugs Archives – Page 5 of 6 – Treatment Action Group

Activists: Call On Your Countries To Use BDQ-Based Regimens to Treat TB

September 27, 2018
Chad Cipiti

GCTA, TAG, and DR-TB STAT developed this letter template to help activists to call for bedaquiline-based, injectable-free regimens in their countries. Please download this template letter here and use it in your country to advocate for the best care possible for people with drug-resistant TB.

In a State of Disunion: HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration

April 3, 2018
Chad Cipiti

By Suraj Madoori During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S. Science and longstanding bipartisan interest in…

It’s up to You, New York: Moving towards HCV Elimination in the Empire State

April 2, 2018
Chad Cipiti

By Annette Gaudino Governor Andrew Cuomo’s March 16 announcement committing New York State (NYS) to ending the hepatitis C virus (HCV) epidemic was the culmination of years of advocacy on a path that paralleled—and is built upon—the state’s nation leading…

Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs

March 31, 2017
Chad Cipiti

With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.

Viekira XR and Technivie Fact Sheet

February 2, 2017
Chad Cipiti

Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination…

Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

January 24, 2017
Chad Cipiti

Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.

TAG Responds to the Release of the World Health Organization’s 2016 Global Tuberculosis Report

October 13, 2016
Chad Cipiti

TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated

Epclusa Fact Sheet

August 31, 2016
Chad Cipiti

Epclusa is a fixed-dose combination of two HCV-fighting drugs (sofosbuvir and velpatasvir) in one pill. In the United States, Epclusa is approved for people with all hepatitis C genotypes (1–6) who are 18 years of age and older.

Zepatier Fact Sheet

April 12, 2016
Chad Cipiti

Zepatier is two hepatitis C virus-fighting drugs in one tablet. These drugs block different steps of the virus lifecycle. In the United States, Zepatier is approved for people who are over 18 years old with hepatitis C genotype 1 or genotype 4.

Solvaldi Fact Sheet

April 2, 2016
Chad Cipiti

Sovaldi (sofosbuvir) is an HCV-fighting drug that must be used with other drugs. In the United States, Sovaldi is approved for people with hepatitis C genotypes 1, 2, 3, or 4 who are over 18 years old.